Shaomeng Wang

Warner-Lambert/Parke-Davis Professor in Medicine
Professor of Medicine, Pharmacology and Medicinal Chemistry
Co-Director, Molecular Therapeutics Program
Director, Cancer Drug Discovery Program

Ph.D., Case Western Reserve University
Postdoctoral Fellow, NIH

Research Focus: Drug design, synthesis, apoptosis, epigenetics, protein-protein interaction, new computational methods for protein-drug interaction

Phone: 734.615.0362
E-mail: shaomeng@med.umich.edu
Fax: 734.764.2532

Dr. Wang's laboratory has a broad interest in design, synthesis, development, in vitro and in vivo molecular mechanism studies of novel small-molecule modulators of apoptosis and cellular signaling, and in preclinical testing and development of molecularly targeted small-molecule therapeutics for the treatment of human cancer and other human disorders. His current research projects include design and development of novel small-molecule anticancer drugs to target key apoptosis regulators including the Bcl-2 family proteins, the inhibitor of apoptosis proteins (IAPs), and the p53-MDM2 interaction.  Dr. Wang's group also develops new computational informatics methods and databases for structure-based drug design, and for studies of structures and functions of proteins and interactions between proteins and small-molecule drugs. An orally active pan-Bcl-2 inhibitor (AT-101) discovered from his laboratory is currently in Phase II clinical trials. A potent and orally active inhibitor of multiple IAP proteins (AT-406) discovered by Dr. Wang’s laboratory is in Phase I clinical trial for cancer treatment. Dr. Wang is working with the National Cancer Institute to advance his potent and orally active small-molecule inhibitors of the MDM2-p53 interaction for cancer treatment. Additional new and exciting projects include the design and development of small-molecule inhibitors targeting the STAT-3 pathway, the WNT/beta-catenin pathway and epigenetic pathways for the treatment of human cancer. Dr. Wang was awarded a National Cooperative Drug Discovery Group Program grant from the National Cancer Institute to develop new anticancer drugs.  Dr. Wang has published over 190 peer-reviewed papers and filed more than 30 patent applications. Dr. Wang is a senior editor of Journal of Medicinal Chemistry.

Wang Research Group


Representative Publications

  1. Yang, C.Y., Sun, H., Chen, J., Nikolovska-Coleska, Z., and Wang, S., "Importance of ligand reorganization free energy in protein-ligand binding-affinity prediction", J. Amer. Chem. Soc., 2009, 131,13709.

  2. Peng, Y., Sun, H., Nikolovska-Coleska, Z., Qiu, S., Yang, C.Y., Lu, J., Cai, Q., Yi, H., Kang, S., Yang, D., and Wang, S., "Potent, orally bioavailable diazabicyclic small-molecule mimetics of second mitochondria-derived activator of caspases", J. Med. Chem., 2008, 51, 8158.

  3. Lu, J., Ba,i L., Sun, H., Nikolovska-Coleska, Z., McEachern, D., Qiu, S., Miller, R.S., Yi, H., Shangary, S., Sun, Y., Meagher, J.L., Stuckey, J.A., and Wang, S., "SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP". Can. Res., 2008, 68, 9384.

  4. Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R.S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., Bernard, D., Zhang, J., Lu, Y., Gu, Q., Shah, R.B., Pienta, K.J., Ling, X., Kang, S., Guo, M., Sun, Y., Yang, D., and Wang, S., "Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition", PNAS, 2008, 105, 3933.

  5. Sun, H., Nikolovska-Coleska, Z., Lu, J., Meagher, J.L., Yang, C.Y., Qiu, S., Tomita, Y., Ueda, Y., Jiang, S., Krajewski, K., Roller, P.P., Stuckey, J.A., and Wang, S., "Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP", J. Am. Chem. Soc., 2007, 129, 15279.

  6. Ding, K., Lu, Y., Nikolovska-Coleska, Z., Wang, G., Qiu, S., Shangary, S., Gao, W., Qin, D., Stuckey, J., Krajewski, K., Roller, P.P., and Wang, S., "Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction", J. Med. Chem., 2006, 49, 3432

  7. Ding, K., Lu, Y., Nikolovska-Coleska, Z., Qiu, S., Ding, Y., Gao, W., Stuckey, J., Krajewski, K., Roller, P.P., Tomita, Y., Parrish, D.A., Deschamps, J.R., and Wang, S., "Structure-based design of potent non-peptide MDM2 inhibitors" J. Am. Chem. Soc., 2005, 127, 10130.